The AEGEAN Phase 3 Trial of Neoadjuvant/Adjuvant Durvalumab in Patients with Resectable Stage II/III NSCLC

被引：20
|
作者：
Heymach, J. [1 ]
Taube, J. [2 ]
Mitsudomi, T. [3 ]
Harpole, D. [4 ]
Aperghis, M. [5 ]
Trani, L. [5 ]
Powell, M. [6 ]
Dennis, P. [6 ]
Reck, M. [7 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Johns Hopkins Univ, Baltimore, MD USA
[3] Kindai Univ, Fac Med, Dept Surg, Div Thorac Surg, Osakasayama, Japan
[4] Duke Univ, Dept Surg, Durham, NC USA
[5] Astrazeneca, Cambridge, England
[6] Astrazeneca, Gaithersburg, MD USA
[7] Airway Res Ctr North, Grosshansdorf, Germany
来源：
JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期
关键词：
Chemotherapy; durvalumab; NSCLC;
D O I：
10.1016/j.jtho.2019.08.1318
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.18-02
引用
收藏
页码：S625 / S626
页数：2
相关论文
共 50 条
  • [1] AEGEAN: a phase 3 trial of neoadjuvant durvalumab plus chemotherapy followed by adjuvant durvalumab in patients with resectable NSCLC
    Schumann, C.
    Heymach, J. V.
    Harpole, D.
    Mitsudomi, T.
    Taube, J. M.
    Galffy, G.
    Hochmair, M.
    Winder, T.
    Zukov, R.
    Garbaos, G.
    Gao, S.
    Kuroda, H.
    You, J.
    Lee, K. -Y.
    Antonuzzo, L.
    Aperghis, M.
    Doherty, G. J.
    Mann, H.
    Fouad, T. M.
    Reck, M.
    Weissinger, F.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 8 - 9
  • [2] Surgical Outcomes with Neoadjuvant Durvalumab plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable NSCLC (AEGEAN)
    Mitsudomi, T.
    Heymach, J. V.
    Reck, M.
    Taube, J. M.
    Gao, S.
    Horio, Y.
    You, J.
    Li, G.
    Van Luong, D.
    Saeteng, S.
    Tanaka, F.
    Kulesza, G.
    Watzka, S. B.
    Urban, L.
    Szalai, Z.
    Akamatsu, H.
    Kang, J. -H.
    Orlandi, F. J.
    Mukhametshina, G. Z.
    Pircher, A.
    Teixeira, C. H. A.
    Aperghis, M.
    Doherty, G. J.
    Doake, R.
    Fouad, T. M.
    Harpole, D.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S71 - S72
  • [3] Neoadjuvant Durvalumab plus Chemotherapy Followed by Adjuvant Durvalumab in Resectable EGFR-mutated NSCLC (AEGEAN)
    He, J.
    Gao, S.
    Reck, M.
    Harpole, D.
    Mitsudomi, T.
    Taube, J. M.
    Lee, K. -Y.
    Horio, Y.
    Runglodvatana, Y.
    Aperghis, M.
    Doherty, G. J.
    Laud, P. J.
    Fouad, T. M.
    Heymach, J. V.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S72 - S73
  • [4] Phase Ib study of neoadjuvant concurrent chemoradiation plus durvalumab followed by surgery and adjuvant durvalumab for resectable stage III NSCLC.
    Lee, Jiyun
    Cho, Jaeho
    Lee, Chang
    Lee, Chang Young
    Lee, Jin Gu
    Kim, Dae Joon
    Shim, Hyo Sup
    Lim, Sun Min
    Kim, Hye Ryun
    Cho, Byoung Chul
    Hong, Min Hee
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [5] Phase Ib Trial of Neoadjuvant Low Dose Radiotherapy, Chemotherapy, and Durvalumab for Potentially Resectable Stage III NSCLC
    Li, J.
    Li, Q.
    Lu, S.
    Jiang, L.
    Li, L.
    Xie, S. -H.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S158 - S159
  • [6] ctDNA dynamics and neoadjuvant treatment responses in patients with resectable NSCLC from the phase 3 AEGEAN trial
    Schumann, Christian
    Heymach, John V.
    Harpole, David
    Mitsudomi, Testuya
    Taube, Janis M.
    Galffy, Gabriella
    Hochmair, Maximilian
    Winder, Thomas
    Zukov, Ruslan
    Garbaos, Gabriel
    Gao, Shugeng
    Kuroda, Hiroaki
    You, Jian
    Lee, Kang-Yun
    Antonuzzo, Lorenzo
    Aperghis, Mike
    Doherty, Gary J.
    Mann, Helen
    Fouad, Tamer M.
    Reck, Martin
    Becker, Silvan
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 126 - 127
  • [7] A Phase Ib Trial of Neoadjuvant Low-Dose Radiation Therapy, Chemotherapy, and Durvalumab for Potentially Resectable Stage III NSCLC
    Li, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1049 - S1050
  • [8] Associations of ctDNA clearance and pathological response with neoadjuvant treatment in patients with resectable NSCLC from the phase III AEGEAN trial
    Reck, M.
    Gale, D.
    Harpole, D.
    Taube, J. M.
    Mitsudomi, T.
    Hochmair, M. J.
    Winder, T.
    Zhu, Z.
    Lai, Z.
    Stewart, R.
    Hodgson, D. R.
    Doherty, G. J.
    Heymach, J. V.
    ANNALS OF ONCOLOGY, 2023, 34 : S1300 - S1300
  • [9] Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab plus Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial
    Heymach, John, V
    Mitsudomi, Tetsuya
    Harpole, David
    Aperghis, Mike
    Jones, Stephanie
    Mann, Helen
    Fouad, Tamer M.
    Reck, Martin
    CLINICAL LUNG CANCER, 2022, 23 (03) : E247 - E251
  • [10] Associations of ctDNA levels during neoadjuvant treatment with pathological response in patients with resectable NSCLC from the phase 3 AEGEAN trial
    Gale, Davina
    Zhu, Zhou
    Lai, Zhongwu
    Reck, Martin
    Harpole, David
    Taube, Janis M.
    Mitsudomi, Tetsuya
    Hochmair, Maximilian
    Winder, Thomas
    Urban, Laszlo
    Rodriguez-Cid, Jeronimo
    Chu, Quincy
    Chaft, Jamie
    Stewart, Ross
    Hodgson, Darren
    Doherty, Gary J.
    Heymach, John V.
    CANCER RESEARCH, 2024, 84 (07)
12345